Merck & Co. Inc. (NYSE:MRK) said FDA granted accelerated approval to Keytruda pembrolizumab to treat recurrent or metastatic cervical cancer with disease progression on or after chemotherapy in patients whose tumors express PD-L1, with a Combined Positive Score (CPS) of ≥1 as determined by an FDA-approved test. The pharma said Keytruda is the first PD-1 inhibitor approved to treat advanced cervical cancer.